6595-28-4

Basic information

• Product Name: Ethanone, 2-azido-1-(4-methoxyphenyl)-
• CAS NO: 6595-28-4
• Molecular Formula: C9H9N3O2
• Molecular Weight: 191.189
• Mol File: 6595-28-4.mol
• Article Data: 83

Chemical Properties

• CAS DataBase Reference: Ethanone, 2-azido-1-(4-methoxyphenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Ethanone, 2-azido-1-(4-methoxyphenyl)-(6595-28-4)
• EPA Substance Registry System: Ethanone, 2-azido-1-(4-methoxyphenyl)-(6595-28-4)

Safety Data

• Hazardous Substances Data: 6595-28-4(Hazardous Substances Data)

Usage

General Description

Ethanone, 2-azido-1-(4-methoxyphenyl)- is a chemical compound with the molecular formula C9H9N3O2. It is a derivative of acetophenone, featuring a 2-azido substitution on the alpha carbon and a 4-methoxy substitution on the phenyl ring. Ethanone, 2-azido-1-(4-methoxyphenyl)- is used in organic synthesis and medicinal chemistry research, particularly in the development of pharmaceuticals and biologically active compounds. Its unique structure and functional groups make it a versatile building block for the creation of novel molecules with various potential applications in the fields of drug discovery and materials science. However, as with all chemical compounds, proper handling and safety precautions are necessary when working with 2-azido-1-(4-methoxyphenyl)-ethanone to prevent potential hazards and ensure safe usage.

Upstream product

• 100-06-1 1-(4-methoxyphenyl)ethanone 
• 2196-99-8 2-chloro-1-(4-methoxyphenyl)ethanone 
• 876-27-7 4-chlorophenyl acetate 
• 144924-01-6 β-azido-α-(4-methoxyphenyl)ethanol 
• 6832-17-3 2-diazo-1-(4-methoxyphenyl)ethanone 
• 93435-57-5 α-tosyloxy-p-methoxyacetophenone 
• 637-69-4 4-Methoxystyrene 
• 55991-65-6 [1-(4-methoxyphenyl)vinyloxy]trimethylsilane 
• 117340-79-1 2-bromo-1-(4-methoxyphenyl)ethanol 
• 2632-13-5 2-Bromo-4'-methoxyacetophenone 

Downstream Products

• 31698-94-9 2-isopropyl-5-(4-methoxyphenyl)oxazole 
• 3988-51-0 (E)-2-(3,4-dimethoxystyryl)-5-(4-methoxyphenyl)oxazole 
• 297765-47-0 (S)-(+)-2-azido-1-(4-methoxyphenyl)-1-ethanol 
• 341513-45-9 (R)-β-azido-α-(4-methoxyphenyl)ethanol 
• 40513-43-7 2-amino-1-(4-methoxy-phenyl)-ethanone 
• 144924-01-6 β-azido-α-(4-methoxyphenyl)ethanol 
• 58144-66-4 (4-methoxyphenyl)(5-phenylisoxazol-3-yl)methanone 
• 1166384-52-6 5-(4-methoxyphenyl)oxazole-4-carboxaldehyde 
• 1150635-10-1 1-(4-methoxyphenyl)-2-(4-phenyl-1H-1,2,3-triazole-1-yl)-1-ethanone 

Relevant articles and documents

Visible-light-induced N-heterocyclic carbene mediated cascade transformation of N-alkenoxypyridinium salts

While N-alkenoxypyridinium salts are widely used for the synthesis of α-functionalized ketones via umpolung strategy, such approaches are usually limited to special nucleophiles at high temperatures. Herein, we developed an alternative photoinduced N-heterocyclic carbene (NHC)- mediated functionalization of N-alkenoxypyridinium salts with various nucleophiles, including tetramethylammonium azide, secondary amines, aryl and alkyl thiols, and even the challenging C(sp3)-nucleophiles, under mild conditions. A cascade radical-radical coupling/nucleophilic substitution sequence was proposed, wherein the NHC enabled the formation of a photoactive electron donor-acceptor complex for α-iodo ketone synthesis.

Indole-linked 1,2,3-triazole derivatives efficiently modulate COX-2 protein and PGE2 levels in human THP-1 monocytes by suppressing AGE-ROS-NF-kβ nexus

Aims: AGEs augment inflammatory responses by activating inflammatory cascade in monocytes, and hence lead to vascular dysfunction. The current study aims to study a plausible role and mechanism of a new library of indole-tethered 1,2,3-triazoles 2-13 in A

Discovery of triazolyl thalidomide derivatives as anti-fibrosis agents

Fibrosis with excessive accumulation of extracellular matrix (ECM) often causes progressive organ dysfunction and results in many inflammatory and metabolic diseases, including systemic sclerosis, pulmonary fibrosis, advanced liver disease and advanced kidney disease. The store-operated calcium entry (SOCE) pathway and the related signaling pathway were both found to be the important routes for fibrogenesis. Our aim in this study was to discover novel compounds to inhibit fibrogenesis. A number of triazolyl thalidomide derivatives were synthesized and evaluated for their anti-fibrosis activities. Compounds 7b-e, 8c-d, 10a-b and 10e inhibited intracellular Ca2+ activation and showed no cytotoxicity. Among them, 6-{4-[(3-(1,3-dioxoisoindolin-2-yl)-2,6-dioxopiperidin-1-yl)methyl]-1H-1,2,3-triazol-1-yl}hexanoic acid (10e) with the most potent inhibitory effect was chosen for further examination. The results revealed that compound 10e, a SOCE inhibitor, reversed the migratory ability of TGF-β1-induced myofibroblasts, dedifferentiated myofibroblasts to fibroblasts due to cytoskeleton remodeling, and restrained myofibroblast activation by targeting Orai1 and TGF-β1/SMAD2/3 signaling pathways. The in silico study indicated that compound 10e, with the appropriate lipophilic carbon chain and carboxylic acid, showed a good drug-likeness model score. Conclusively, the SOCE inhibitor, compound 10e, is used as a promising lead compound for the development of a new treatment for fibrosis. This journal is